Radius Health Inc (NASDAQ:RDUS) – Jefferies Financial Group lifted their FY2023 earnings per share estimates for shares of Radius Health in a report issued on Wednesday, May 8th. Jefferies Financial Group analyst E. Yang now anticipates that the biopharmaceutical company will post earnings per share of $1.47 for the year, up from their previous forecast of $1.32.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.32. The business had revenue of $34.42 million during the quarter, compared to analyst estimates of $33.99 million. Radius Health had a negative return on equity of 191.58% and a negative net margin of 176.84%.
A number of other research analysts have also weighed in on RDUS. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. HC Wainwright initiated coverage on Radius Health in a research report on Thursday, February 14th. They set a “neutral” rating and a $22.00 price target for the company. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Cowen reiterated a “hold” rating on shares of Radius Health in a research report on Wednesday, May 8th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $38.00.
RDUS stock opened at $21.47 on Monday. The company has a quick ratio of 5.79, a current ratio of 5.92 and a debt-to-equity ratio of 2.97. The stock has a market cap of $930.90 million, a price-to-earnings ratio of -4.40 and a beta of 0.98. Radius Health has a twelve month low of $12.81 and a twelve month high of $33.53.
A number of large investors have recently added to or reduced their stakes in RDUS. Teachers Advisors LLC lifted its position in Radius Health by 503.7% in the 3rd quarter. Teachers Advisors LLC now owns 446,277 shares of the biopharmaceutical company’s stock worth $7,944,000 after buying an additional 372,355 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Radius Health by 1,624,525.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 259,940 shares of the biopharmaceutical company’s stock worth $5,183,000 after buying an additional 259,924 shares during the last quarter. Norges Bank bought a new stake in Radius Health in the 4th quarter worth approximately $4,057,000. DekaBank Deutsche Girozentrale lifted its position in Radius Health by 1,098.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 189,400 shares of the biopharmaceutical company’s stock worth $3,739,000 after buying an additional 173,600 shares during the last quarter. Finally, BB Biotech AG lifted its position in Radius Health by 1.8% in the 4th quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after buying an additional 120,000 shares during the last quarter.
In related news, Director Willard H. Dere sold 1,680 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $22.22, for a total value of $37,329.60. Following the completion of the sale, the director now owns 8,620 shares in the company, valued at approximately $191,536.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Debasish Roychowdhury sold 4,800 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total value of $106,320.00. Following the completion of the sale, the director now owns 5,500 shares of the company’s stock, valued at approximately $121,825. The disclosure for this sale can be found here. Company insiders own 4.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: Special Dividends
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.